Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-DART-NK01
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-DART-NK01 is an allogeneic, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech for the treatment of relapsed or refractory small cell lung cancer (SCLC). The therapy utilizes NK cells engineered to express CARs targeting two tumor-associated antigens: Delta-like ligand 3 (DLL3) and Neural Cell Adhesion Molecule 1 (CD56/NCAM1). DLL3 is a notch ligand inhibitor highly expressed in SCLC but minimally in normal tissues, while CD56 is a glycoprotein involved in cell-cell adhesion often found on neuroendocrine tumors. By targeting both antigens, EB-DART-NK01 aims to enhance tumor recognition and overcome antigen escape. As an allogeneic product, it offers the potential for "off-the-shelf" availability and a reduced risk of graft-versus-host disease compared to T-cell therapies.
- Other names
- DLL3/CD56 CAR-NK cells
02
Targets
DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on EB-DART-NK01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-DART-NK01.